(Q84903906)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Daniel F Hayes

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

18 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

S131-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Adjuvant therapy of node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970287-5

7 January 2021

10.1016/S0960-9776(09)70287-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914531%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference